评论 Larance 等人（2020 年）：扩大使用 XR-丁丙诺啡的重点和关注点是使用阿片类药物的人的关键。
Commentary on Larance et al. (2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine.
机构信息
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 1070 Arastradero Rd. Ste 200, Palo Alto, CA, USA.
出版信息
Addiction. 2020 Jul;115(7):1306-1307. doi: 10.1111/add.15048. Epub 2020 Apr 18.
Abstract
Larence et al.’s findings have key implications for XR-buprenorphine guidelines as it becomes available internationally. These are to embrace less-onerous dosing schedules, to consider incorporating into standard-of-care an option to supplement with transmucosal buprenorphine between injections, and to investigate what possibilities XR-buprenorphine opens up for patients wanting to taper off opioid agonist treatment.
摘要
劳伦斯等人的研究结果对 XR-丁丙诺啡国际应用指南具有重要意义。这些建议包括采用更少侵入性的给药方案，考虑在标准治疗中加入一种选择，即在注射之间用透黏膜丁丙诺啡进行补充，并研究 XR-丁丙诺啡为希望逐渐减少阿片类激动剂治疗的患者提供了哪些可能性。
相似文献
1
Commentary on Larance et al. (2020): Priorities and concerns of people who use opioids are key to scaling up XR-buprenorphine.评论 Larance 等人（2020 年）：扩大使用 XR-丁丙诺啡的重点和关注点是使用阿片类药物的人的关键。
Addiction. 2020 Jul;115(7):1306-1307. doi: 10.1111/add.15048. Epub 2020 Apr 18.
2
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.出狱后对纳曲酮、美沙酮和丁丙诺啡延长释放治疗的看法。
Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166-0.
3
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.对谢勒等人（2014年）的评论：阿片类药物维持治疗中保留或不保留的开放性问题
Addiction. 2014 Jan;109(1):88-9. doi: 10.1111/add.12376.
4
Buprenorphine implants in medical treatment of opioid addiction.丁丙诺啡植入剂用于阿片类药物成瘾的医学治疗。
Expert Rev Clin Pharmacol. 2017 Aug;10(8):799-807. doi: 10.1080/17512433.2017.1336434. Epub 2017 Jun 21.
5
Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.对考辛斯等人（2016年）的评论：关于阿片类药物替代治疗期间及停药后死亡风险的证据不断积累。
Addiction. 2016 Jan;111(1):83-4. doi: 10.1111/add.13185.
6
Commentary on Freelemyer et al. (2014): medication-assisted treatment in Africa-need is growing but response remains tepid.对弗里勒迈尔等人（2014年）的评论：非洲药物辅助治疗——需求不断增长，但反应依然冷淡。
Addiction. 2014 Jan;109(1):33-4. doi: 10.1111/add.12364.
7
Medications for management of opioid use disorder.阿片类药物使用障碍的药物治疗。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105.
8
[New slow-release buprenorphine formulations for optimization of opioid substitution].[用于优化阿片类药物替代治疗的新型缓释丁丙诺啡制剂]
Nervenarzt. 2019 Sep;90(9):932-937. doi: 10.1007/s00115-019-0783-6.
9
Medication Treatment of Opioid Use Disorder.阿片类药物使用障碍的药物治疗。
Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2.
10
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.每月一次丁丙诺啡储库注射治疗阿片类药物使用障碍的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.
引用本文的文献
1
Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022.2018-2022 年医疗补助受益人为开处丁丙诺啡透皮贴剂的情况。
Addiction. 2024 Dec;119(12):2211-2215. doi: 10.1111/add.16652. Epub 2024 Aug 16.
2
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.美沙酮患者阿片类药物使用障碍治疗中，纳曲酮缓释片与丁丙诺啡舌下片的疗效比较。
Addiction. 2024 Nov;119(11):1975-1986. doi: 10.1111/add.16630. Epub 2024 Aug 5.
3
Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.缓释纳曲酮与舌下含服丁丙诺啡治疗医疗补助患者阿片类物质使用障碍的比较疗效
medRxiv. 2024 Apr 1:2024.01.24.24301555. doi: 10.1101/2024.01.24.24301555.
4
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.描述一个具有全国代表性的美国商业保险队列中，延长释放丁丙诺啡的起始使用、持续使用和停止使用情况。
Drug Alcohol Depend. 2021 Aug 1;225:108764. doi: 10.1016/j.drugalcdep.2021.108764. Epub 2021 May 21.
本文引用的文献
1
Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.澳大利亚经常使用阿片类药物的人群对用于治疗阿片类药物使用障碍的丁丙诺啡延长释放注射剂的看法。
Addiction. 2020 Jul;115(7):1295-1305. doi: 10.1111/add.14941. Epub 2020 Feb 5.
2
Predictors of availability of long-acting medication for opioid use disorder.阿片类药物使用障碍长效药物供应的预测因素。
Drug Alcohol Depend. 2019 Nov 1;204:107586. doi: 10.1016/j.drugalcdep.2019.107586. Epub 2019 Sep 25.
3
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.每月一次丁丙诺啡储库注射治疗阿片类药物使用障碍的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.
4
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.在美国商业保险人群中，接受阿片类药物使用障碍治疗的个体中，可注射纳曲酮、口服纳曲酮和丁丙诺啡的使用和停药情况。
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
Zotero 插件